Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Colorectal Neoplasms × zimberelimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1 Solid Tumor 1 Prostatic Neoplasms, Castration-Resistant 1 Pancreatic Neoplasms 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

Cetuximab 39 Irinotecan 31 pembrolizumab 30 Capecitabine 30 Oxaliplatin 28 Bevacizumab 28 Fluorouracil 26 Leucovorin 24 Nivolumab 17 Gemcitabine 12 Cyclophosphamide 12 regorafenib 10 Folfox protocol 10 Pemetrexed 9 Cisplatin 9 Carboplatin 9 Paclitaxel 8 IFL protocol 8 tislelizumab 7 Panitumumab 7 130-nm albumin-bound paclitaxel 7 durvalumab 6 HMPL-013 6 Drug Therapy 6 irinotecan sucrosofate 5 Trifluridine 5 Specimen Handling 5 Ipilimumab 5 Docetaxel 5 trametinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04660812 2025-10-20

ARC-9

Arcus Biosciences, Inc.

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡